natgillin/translations-raw huggingface dataset:
However, a higher percentage of subjects in the cobicistat-boosted group had increases in total bilirubin > 2 x ULN than those in the ritonavir-boosted group (88.0% versus 80.9%). 
Vendar pa je imel višji odstotek bolnikov v skupini skupini zdravila, okrepljenega s kobicistatom, povišan skupni bilirubin > 2 x ULN kot v skupini zdravila, okrepljenega z ritonavirjem (88,0 % v primerjavi s 80,9 %).
• vomiting, diarrhoea, stomach pain, problems with digestion resulting in pain after meals 
• bruhanje, driska, bolečine v trebuhu, težave s prebavo, ki po obroku povzročijo bolečine
Other medicines and Tybost Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali boste morda začeli jemati katero koli drugo zdravilo.
• Do not breast-feed during treatment with Tybost. 
• Med zdravljenjem z zdravilom Tybost ne dojite.
In Study GS-US-216-0114, decreases in estimated creatinine clearance occurred early in treatment with cobicistat, after which they stabilised. 
V študiji GS-US-216-0114 se je znižanje ocenjenega očistka kreatinina pri zdravljenju s kobicistatom pojavilo na začetku zdravljenja, nakar se je stabiliziralo.
 If any of these applies to you, you should not take Tybost and you should tell your doctor immediately. 
 Če to velja za vas, ne jemljite zdravila Tybost in o tem nemudoma obvestite svojega zdravnika.
For medicinal products metabolised by CYP3A these higher plasma concentrations may potentially lead to serious and/or life-threatening events (see section 4.3). 
Pri zdravilih, ki jih presnavlja CYP3A, lahko te višje koncentracije v plazmi povzročijo resne in/ali življenjsko nevarne dogodke (glejte poglavje 4.3).
No teratogenic effects were observed in rats and rabbit developmental toxicity studies. 
V študijah razvojne toksičnosti pri podganah in kuncih niso opazili teratogenih učinkov.
It is important not to miss a dose of Tybost. 
Pomembno je, da ne pozabite vzeti nobenega odmerka zdravila Tybost.
Tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (HIV-1) infected adults. 
Zdravilo Tybost je indicirano kot farmakokinetični ojačevalec atazanavirja 300 mg enkrat na dan ali darunavirja 800 mg enkrat na dan kot del protiretrovirusnega kombiniranega zdravljenja pri odraslih, okuženih z virusom humane imunske pomanjkljivosti 1 (HIV-1).
Co-administration is contraindicated with medicinal products that are strong inducers of CYP3A due to the potential for loss of therapeutic effect. 
Sočasno dajanje je kontraindicirano z zdravili, ki so močni induktorji CYP3A zaradi potencialne izgube terapevtskega učinka.
The active substance cobicistat is persistent in the environment. 
Učinkovina kobicistat je v okolju obstojna.
• sildenafil and vardenafil, medicines used to treat impotence, and tadalafil, a medicine used to treat impotence and pulmonary hypertension 
• sildenafil in vardenafil; zdravili, ki se uporabljata za zdravljenje impotence, in tadalafil, zdravilo, ki se uporablja za zdravljenje impotence in pljučne hipertenzije
Co-administration is not recommended. 
Sočasnega dajanja se ne priporoča.
Digoxin: 
digoksin:
• trazodone, a medicine used to treat depression 
• trazodon; zdravilo, ki se uporablja za zdravljenje depresije
Each tablet contains 59 micrograms sunset yellow FCF aluminium lake (E110). 
Ena tableta vsebuje 59 mikrogramov barvila sončno rumeno FCF (E110).
Therefore, Tybost should not be used during breast-feeding. 
Zdravila Tybost se med dojenjem ne sme uporabljati.
See sections 4.4, 4.8 and 5.2. 
Glejte poglavja 4.4, 4.8 in 5.2.
In treatment-naïve HIV-1 infected patients 
Pri predhodno nezdravljenih bolnikih, okuženih s HIV-1
Sunset yellow FCF aluminium lake (E110), macrogol 3350 (E1521), polyvinyl alcohol (partially hydrolysed) (E1203), talc (E553B), titanium dioxide (E171), iron oxide yellow (E172) (see section 2 of this leaflet). 
Barvilo sončno rumeno FCF (E110), makrogol 3350 (E1521), polivinilalkohol (delno hidroliziran) (E1203), smukec (E553B), titanov dioksid (E171), rumeni železov oksid (E172) (glejte poglavje 2 v tem navodilu).
An increase from baseline in serum creatinine solely due to cobicistat's inhibitory effect generally does not exceed 0.4 mg/dl. 
Zvišanje serumskega kreatinina samo zaradi zaviralnega učinka kobicistata v primerjavi z izhodiščnimi vrednostmi v splošnem ne preseže 0,4 mg/dl.
Cobicistat is a weak CYP2D6 inhibitor and is metabolised to a minor extent by CYP2D6. 
Kobicistat je šibak zaviralec CYP2D6, ki ga v manjšem obsegu presnavlja CYP2D6.
Following oral administration of [14C]cobicistat, 86% and 8.2% of the dose were recovered in faeces and urine, respectively. 
Po peroralni uporabi [14C]kobicistata so 86 % in 8,2 % odmerka izolirali iz blata oz. urina.
High density polyethylene (HDPE) bottle with a polypropylene child-resistant closure containing 30 film-coated tablets and a silica gel desiccant. 
Plastenka iz polietilena visoke gostote (HDPE) s polipropilensko, za otroke varno zaporko, ki vsebuje 30 filmsko obloženih tablet in silikagelsko sušilno sredstvo.
• increased levels of bilirubin in the blood (hyperbilirubinaemia) 
• zvišane ravni bilirubina v krvi (hiperbilirubinemija)
Missing data during window but on study drug a Week 48 window is between day 309 and 378 (inclusive) b Week 144 window is between day 967 and 1,050 (inclusive) c Includes subjects who had ≥ 50 copies/ml in the week 48 or 144 windows; subjects who discontinued early due to lack or loss of efficacy; subjects who discontinued for reasons other than an adverse event, death or lack or loss of efficacy, and at the time of discontinuation had a viral value of ≥ 50 copies/ml. 
V oknu podatki manjkajo, a uporablja študijsko zdravilo a Okno 48. tedna je med 309. in 378. dnevom (vključno z njima) b Okno 144. tedna je med 967. in 1.050. dnevom (vključno z njima) c Vključuje osebe, ki so imele v oknu 48. ali 144. tedna ≥ 50 kopij/ml; osebe, ki so predčasno prekinile sodelovanje zaradi pomanjkanja ali izgube učinkovitosti; osebe, ki so sodelovanje prekinile zaradi razlogov,
Cobicistat is primarily metabolised and eliminated by the liver. 
Kobicistat v glavnem presnavljajo in izločajo jetra.
Tybost must not be used as a pharmacokinetic enhancer of any other HIV-1 protease inhibitor or any other antiretroviral medicinal product that requires boosting since dosing recommendations for such co-administration have not been established and may result in insufficient plasma level of the antiretroviral medicinal product(s) leading to loss of therapeutic effect and development of resistance (see section 4.2). 
Zdravila Tybost se ne sme uporabljati kot farmakokinetični ojačevalec katerih koli drugih zaviralcev proteaze HIV-1 ali protiretrovirusnih zdravil, ki jih je treba okrepiti, ker priporočil za takšno sočasno odmerjanje niso opredelili in lahko vodi v nezadostne ravni protiretrovirusnega(ih) zdravil(a) v plazmi, kar vodi v izgubo terapevtskega učinka in razvoj rezistence (glejte poglavje 4.2).
Cobicistat has been shown to decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine. 
Pokazalo se je, da kobicistat zmanjšuje ocenjeni očistek kreatinina zaradi zaviranja tubularne sekrecije kreatinina.
Orange, round, biconvex, film-coated tablet of diameter 10.3 mm, debossed with “GSI” on one side of the tablet and plain-faced on the other side of the tablet. 
Oranžna, okrogla, bikonveksna, filmsko obložena tableta s premerom 10,3 mm, z vtisnjenim znakom "GSI" na eni strani tablete in brez oznak na drugi strani tablete.
When administering with cobicistat, the maximum daily dose of itraconazole should not exceed 200 mg per day. 
Pri dajanju kobicistata največji dnevni odmerek itrakonazola ne sme preseči 200 mg dnevno.
Cobicistat exposures are non-linear and greater than dose-proportional over the range of 50 mg to 400 mg, consistent with a mechanism-based CYP3A inhibitor. 
Izpostavljenosti kobicistatu so nelinearne in več kot sorazmerne z odmerkom v razponu od 50 mg do 400 mg, kar je v skladu s tem, da je zaviralec encimskega mehanizma CYP3A.
It is recommended to start with the lowest recommended dose of rosuvastatin and titrate based on clinical response while monitoring for safety (e.g. myopathy). 
Priporočljivo je začeti z najnižjim priporočljivim odmerkom rosuvastatina in ga titrirati na podlagi kliničnega odziva, obenem pa bolnika spremljati zaradi varnosti (npr. miopatija).
Tablet core Croscarmellose sodium, magnesium stearate, microcrystalline cellulose, silicon dioxide. 
Jedro tablete Premreženi natrijev karmelozat, magnezijev stearat, mikrokristalna celuloza, silicijev dioksid.
Unlike ritonavir, cobicistat is not an inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or UGT1A1. 
V nasprotju z ritonavirjem kobicistat ni induktor CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 ali UGT1A1.
What Tybost looks like and contents of the pack 
Izgled zdravila Tybost in vsebina pakiranja
• high sugar levels in the blood (hyperglycaemia) 
• visoka raven sladkorja v krvi (hiperglikemija)
For the treatment of erectile dysfunction, it is recommended that a single dose of sildenafil no more than 25 mg in 48 hours, vardenafil no more than 2.5 mg in 72 hours, or tadalafil no more than 10 mg in 72 hours be co-administered with Tybost. 
Za zdravljenje erektilne disfunkcije se pri sočasni uporabi z zdravilom Tybost priporoča enkratni odmerek sildenafila največ 25 mg v 48 urah, vardenafila največ 2,5 mg v 72 urah ali tadalafila največ 10 mg v 72 urah.
• sedatives/hypnotics: orally administered midazolam, triazolam 
• sedativi/hipnotiki: peroralno uporabljeni midazolam, triazolam
The steady-state mean Cmax, AUCtau, and Ctrough (mean ± SD) following multiple doses of cobicistat in HIV-1 infected subjects (n = 68), respectively, were 1.2 ± 0.3 µg/ml, 10.9 ± 3.8 µg•h/ml, and 0.07 ± 0.07 µg/ml. 
Povprečni Cmax, AUCtau in Ctrough (povprečje ± SD) v stanju dinamičnega ravnovesja po večkratnem odmerjanju kobicistata osebam, okuženim z virusom HIV-1 (n = 68), so bili 1,2 ± 0,3 μg/ml, 10,9 ± 3,8 μg•h/ml oz. 0,07 ± 0,07 μg/ml.
Treatment with cobicistat and darunavir during pregnancy results in lower darunavir exposure which may be associated with an increased risk of virological failure and an increased risk of mother-to-child transmission of HIV infection. 
Zdravljenje s kobicistatom in darunavirjem med nosečnostjo povzroči manjšo izpostavljenost darunavirju, kar je lahko povezano s povečanim tveganjem za virološki neuspeh in povečanim tveganjem za prenos okužbe s HIV z matere na otroka.
• anticonvulsants: carbamazepine, phenobarbital, phenytoin 
• antikonvulzanti: karbamazepin, fenobarbital, fenitoin
• atorvastatin, fluvastatin, pitavastatin, pravastatin and rosuvastatin, medicines used to lower cholesterol 
• atorvastatin, fluvastatin, pitavastatin, pravastatin in rosuvastatin; zdravila, ki se uporabljajo za nižanje holesterola
See sections 4.2, 4.8 and 5.2. 
Glejte poglavji 4.2, 4.8 in 5.2.
• salmeterol, a medicine used to treat asthma 
• salmeterol; zdravilo, ki se uporablja za zdravljenje astme
Co-administration is contraindicated with medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. 
Sočasno dajanje je kontraindicirano z zdravili, katerih očistek je močno odvisen od CYP3A in pri katerih so povišane koncentracije v plazmi povezane z resnimi in/ali življenjsko nevarnimi dogodki.
Cobicistat is not expected to inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9 or CYP2C19. 
Ne pričakuje se, da bi kobicistat zaviral CYP1A2, CYP2B6, CYP2C8, CYP2C9 ali CYP2C19.
Tybost film-coated tablets are orange, round, biconvex tablets, debossed on one side with “GSI” and plain-faced on the other side of the tablet. 
Zdravilo Tybost filmsko obložene tablete so oranžne, okrogle, bikonveksne tablete z vtisnjeno oznako "GSI" na eni strani tablete in brez oznak na drugi strani tablete.
• metformin, medicine used for the treatment of type 2 diabetes 
• metformin; zdravilo, ki se uporablja za zdravljenje sladkorne bolezni tipa 2
Percentage of subjects with viral load 
Odstotek oseb s številom celic
No human data on the effect of cobicistat on fertility are available. 
Podatkov o vplivu kobicistata na plodnost pri ljudeh ni na voljo.
Rilpivirine is not expected to affect the plasma concentration of cobicistat. 
Ne pričakuje se, da bi rilpivirin vplival na koncentracijo kobicistata v plazmi.
Week 144 
48. teden
• headache, dizziness 
• glavobol, omotičnost
Safety and efficacy have not been established for use of cobicistat with either atazanavir or darunavir when used in any other dosing regimen. 
Varnost in učinkovitost uporabe kobicistata z bodisi atazanavirjem ali darunavirjem, če se uporabljata v drugih režimih odmerjanja, nista bili dokazani.
Do not stop taking Tybost Do not stop taking Tybost without talking to your doctor. 
Ne prenehajte jemati zdravila Tybost, ne da bi se posvetovali s svojim zdravnikom.
• antiarrhythmics: amiodarone, quinidine 
• antiaritmiki: amiodaron, kinidin
Some patients have reported dizziness when Tybost was taken with atazanavir or darunavir. 
Nekateri bolniki so med jemanjem zdravila Tybost z atazanavirjem ali darunavirjem poročali o omotici.
If you accidentally take more than the recommended dose of Tybost you may be at increased risk of experiencing side effects with this medicine (see section 4 of this leaflet). 
Če ste pomotoma zaužili odmerek zdravila Tybost, večji od priporočenega, obstaja povečano tveganje za pojav neželenih učinkov (glejte poglavje 4 tega navodila).
Co-administration of salmeterol and Tybost is not recommended (see section 4.4). 
Sočasnega dajanja zdravila Tybost in salmeterola se ne priporoča (glejte poglavje 4.4).
Among the 21 patients, 3 developed the emtricitabine-associated resistance substitution M184V. 
Pri 3 od 21 bolnikov se je razvila substitucija M184V, povezana z rezistenco na emtricitabin.
(may affect more than 1 in 10 people) 
Zelo pogosti neželeni učinki (pojavijo se lahko pri več kot 1 od 10 oseb)
headache, dizziness, somnolence, dysgeusia 
glavobol, omotica, somnolenca, disgevzija
• bosentan, a medicine used to treat pulmonary arterial hypertension 
• bosentan; zdravilo, ki se uporablja za zdravljenje pljučne arterijske hipertenzije
Plasma concentrations of these medicinal products may be increased when co-administered with cobicistat, resulting in reduced serum cortisol concentrations. 
Plazemske koncentracije teh zdravil se lahko ob sočasnem dajanju zdravila kobicistata povečajo, kar povzroči zmanjšanje serumskih koncentracij kortizola.
The effect of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of cobicistat has not been studied. 
Učinka hude jetrne okvare (stopnja C po Child-Pughu) na farmakokinetične lastnosti kobicistata niso proučevali.
If a patient misses a dose of Tybost by more than 12 hours, the patient should not take the missed dose and simply resume the usual dosing schedule. 
Tybost za več kot 12 ur, naj bolnik ne nadomesti izpuščenega odmerka in preprosto nadaljuje z jemanjem po običajnem režimu odmerjanja.
Co-administration is not recommended (see section 4.4). 
Sočasna uporaba se ne priporoča (glejte poglavje 4.4).
[Outer packaging only] 
[samo na zunanji ovojnini]
• ergot derivatives: dihydroergotamine, ergometrine, ergotamine 
• derivati ergot-alkaloidov: dihidroergotamin, ergometrin, ergotamin
PHOSPHODIESTERASE TYPE-5 (PDE-5) INHIBITORS Sildenafil 
ZAVIRALCI FOSFODIESTERAZE TIPA 5 (PDE5)
No meaningful differences in cobicistat pharmacokinetics were observed between subjects with severe renal impairment and healthy subjects, consistent with low renal clearance of cobicistat. 
Pomembnih razlik v farmakokinetičnih lastnostih kobicistata med osebami s hudo ledvično okvaro in zdravimi osebami niso opazili, kar je v skladu z nizkim ledvičnim očistkom kobicistata.
vomiting, diarrhoea, dyspepsia, abdominal pain, abdominal distension, flatulence, dry mouth Hepatobiliary disorders: Very common: 
bruhanje, driska, dispepsija, bolečine v trebuhu, abdominalna distenzija, flatulenca, suha usta Bolezni jeter, žolčnika in žolčevodov: Zelo pogosti:
K65R or K70E, or any primary resistance substitution associated with protease inhibitors. 
Pri nobeni osebi se ni razvila substitucija K65R ali K70E, povezana z rezistenco na tenofovir, ali primarna rezistenčna substitucija, povezana z zaviralci proteaze.
Therefore, the use of Tybost is not recommended in these patients (see sections 4.2 and 5.2). 
Zato se uporabe zdravila Tybost pri teh bolnikih ne priporoča (glejte poglavji 4.2 in 5.2).
The doses of Tybost and the co-administered protease inhibitor, atazanavir or darunavir, are presented in Table 1. 
Odmerek zdravila Tybost in zaviralca proteaze, ki se daje sočasno, atazanavirja ali darunavirja, je predstavljen v preglednici 1.
Co-administration of cobicistat with medicinal products such as dihydroergotamine, ergotamine, ergometrine, orally administered midazolam, triazolam, amiodarone, quinidine, pimozide, lurasidone, alfuzosin, simvastatin, lovastatin, and sildenafil which are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated (see section 4.3). 
Sočasno dajanje kobicistata z zdravili, kot so dihidroergotamin, ergotamin, ergometrin, peroralno uporabljeni midazolam, triazolam, amiodaron, kinidin, pimozid, lurasidon, alfuzosin, simvastatin, lovastatin in sildenafil, katerih očistek je močno odvisen od CYP3A in pri katerih so zvišane koncentracije v plazmi povezane z resnimi in/ali življenjsko nevarnimi dogodki, je kontraindicirano (glejte poglavje 4.3).
Therefore, Tybost should not be co-administered with medicinal products that include, but are not limited to, the following (see sections 4.4 and 4.5): 
Zdravila Tybost se zato ne sme dajati sočasno z zdravili, ki med drugim vsebujejo naslednje (glejte poglavji 4.4 in 4.5):
Table 4: Pharmacokinetic parameters [mean ± SD (%CV)] of atazanavir in the pharmacokinetic sub-study of phase 3 Study GS-US-216-0114 
Preglednica 4: Farmakokinetični parametri [povprečje ± SD (% KV)] atazanavirja v farmakokinetični podštudiji študije faze 3 GS-US-216-0114
Following oral administration of cobicistat with food in HIV-1 infected subjects, peak plasma concentrations were observed 4 hours post-dose for cobicistat. 
Po peroralnem dajanju kobicistata s hrano osebam, okuženim z virusom HIV-1, so najvišje plazemske koncentracije opazili 4 ure po odmerku kobicistata.
Low levels of metabolites are observed in urine and faeces and do not contribute to the CYP3A inhibitory activity of cobicistat. 
V urinu in blatu so opazili nizke ravni presnovkov, ki ne prispevajo k aktivnosti kobicistata pri zaviranju CYP3A.
The pharmacokinetics of cobicistat in paediatric subjects have not been established. 
Farmakokinetične lastnosti kobicistata pri pediatričnih bolnikih niso ugotovljene.
ENDOTHELIN RECEPTOR ANTAGONISTS Bosentan 
ANTAGONISTI RECEPTORJEV ENDOTELINA
Some examples include, but are not limited to, etravirine, efavirenz, nevirapine, and bosentan (see Table 2). 
To so med drugim etravirin, efavirenz, nevirapin in bosentan, vendar pa niso omejeni nanje (glejte preglednico 2).
Co-administration of cobicistat with medicinal products that induce CYP3A is contraindicated or is not recommended (see sections 4.3 and 4.5) because decreased plasma concentrations of cobicistat could result in plasma levels that are insufficient to achieve adequate pharmacoenhancement of atazanavir or darunavir. 
Sočasno dajanje kobicistata z zdravili, ki inducirajo CYP3A, je kontraindicirano ali se ne priporoča (glejte poglavji 4.3 in 4.5), ker lahko zmanjšanje plazemskih koncentracij kobicistata v plazmi vodi v ravni, ki ne zadoščajo za doseganje ustrezne farmakokinetične okrepitve atazanavirja ali darunavirja.
PDE-5 inhibitors are primarily metabolised by CYP3A. 
Zaviralce PDE-5 presnavlja pretežno CYP3A.
Pharmacokinetics of cobicistat have not been fully evaluated in hepatitis B and/or C virus co-infected subjects. 
Farmakokinetičnih lastnosti kobicistata pri bolnikih s sočasno okužbo z virusom hepatitisa B in/ali C niso v celoti ovrednotili.
The following pack sizes are available: outer cartons containing 1 bottle of 30 film-coated tablets and 90 (3 bottles of 30) film-coated tablets. 
Na voljo so naslednje velikosti pakiranj: škatle z 1 plastenko s po 30 filmsko obloženimi tabletami in 90 (3 plastenke po 30) filmsko obloženimi tabletami.
• another protease inhibitor 
• drugega zaviralca proteaze
Viruses were known to be susceptible to atazanavir, emtricitabine and tenofovir disoproxil fumarate at baseline. 
Za viruse je bilo ob začetku študije znano, da so občutljivi na atazanavir, emtricitabin in dizoproksiltenofovirat fumarat.
Median age, years (min-max) 
Demografske značilnosti Mediana starost, leta (najmanj-največ)
Then take the next dose as usual in combination with atazanavir or darunavir. 
Nato vzemite naslednji odmerek v kombinaciji z atazanavirjem ali darunavirjem ob svojem običajnem času.
• blood in the urine (haematuria) 
• kri v urinu (hematurija)
Dose titration may be required for most medicinal products of the SSRI class, when co-administered with Tybost. 
Za večino zdravil razreda SSRI bo morda treba pri sočasni uporabi z zdravilom Tybost odmerek titrirati.
Eye disorders: Very common: 
Očesne bolezni: Zelo pogosti:
Concomitant use of cobicistat and corticosteroids that are metabolised by CYP3A (e.g. fluticasone propionate or other inhaled or nasal corticosteroids) may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression. 
Sočasna uporaba kobicistata in kortikosteroidov, ki se presnavljajo s pomočjo encimov CYP3A (npr. flutikazonpropionat in drugi inhalacijski ali nazalni kortikosteroidi), lahko poveča tveganje za razvoj sistemskih kortikosteroidnih učinkov, vključno s Cushingovim sindromom in supresijo nadledvičnih žlez.
The most frequently reported adverse reactions to cobicistat-boosted atazanavir were associated with elevated bilirubin levels (see Table 3). 
Najpogostejši neželeni učinki, ki so jih poročali za atazanavir, okrepljen s kobicistatom, so bili povezani z zvišanimi ravnmi bilirubina (glejte preglednico 3).
HMG Co-A REDUCTASE INHIBITORS Fluvastatin 
ZAVIRALCI REDUKTAZE HMG CoA
It is recommended that Tybost be administered with food. 
Priporoča se uporabo zdravila Tybost skupaj s hrano.
Itraconazole Voriconazole Posaconazole Fluconazole 
itrakonazol iorikonazol posakonazol flukonazol
• ciclosporin, sirolimus and tacrolimus, medicines used to control your body's immune response after a transplant 
• ciklosporin, sirolimus in takrolimus; zdravila za nadzor imunskega odziva telesa po presaditvi
Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates (such as atazanavir or darunavir) that have limited oral bioavailability and a short half-life due to CYP3A-dependent metabolism. 
Zaviranje presnove preko CYP3A s kobicistatom okrepi sistemsko izpostavljenost substratov CYP3A (kot sta atazanavir ali darunavir), ki imajo omejeno peroralno biološko uporabnost in kratek razpolovni čas zaradi presnove, odvisne od CYP3A.
The effect of cobicistat on serum creatinine and eGFR in patients switching from ritonavir to cobicistat in Study GS-US-236-0118 was consistent with the effect in treatmentnaïve patients in Study GS-US-216-0114. 
Učinek kobicistata na raven kreatinina v serumu in eGFR pri bolnikih, ki so v študiji GS-US-236-0118 z ritonavirja prešli na kobicistat, je bil skladen z učinkom pri bolnikih v študiji GS-US-216-0114, ki se predhodno še niso zdravili.
Maraviroc is a substrate of CYP3A and its plasma concentration increases when co-administered with potent CYP3A inhibitors. 
Maravirok je substrat CYP3A, njegova koncentracija v plazmi pa se ob sočasni uporabi z močnimi zaviralci CYP3A zviša.
Recommendation concerning co-administration with cobicistat 150 mg and atazanavir or darunavir 
Priporočilo glede sočasne uporabe s kobicistatom 150 mg in atazanavirjem ali darunavirjem nevirapin